ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Jehangir Hospital continues to revolutionize healthcare in Pune, setting benchmarks in patient care and medical excellence.

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

Dr Sundeep Salvi: Shardul Nautiyal, Mumbai Tuesday, March 4, 2025, 08:00 Hrs [IST] Chronic obstructive pulmonary disease (C ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

U.S. Home Medical Equipment Market 2035 PORTLAND, KS, UNITED STATES, March 3, 2025 /EINPresswire / -- Increase in prevalence of chronic diseas ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990 ...

Certain medications commonly used to treat asthma and COPD can damage the environment and worsen respiratory issues. KYW ...

First New Treatment for Asthma Attacks in 50 Years Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of ...

Pope Francis experienced a serious health scare with a bronchial spasm after inhaling vomit, complicating his recovery from ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...